This site is intended for healthcare professionals
CDK4/6 inhibitor selection in metastatic breast cancer

Expert opinion

Discover what our medical experts say on the clinical utility of CDK4/6 inhibitors (abemaciclib, ribociclib and palbociclib) for HR+/HER2- metastatic breast cancer, and the key considerations when selecting the right CDK4/6 inhibitor for your patient.

This content has been developed independently of the sponsor, Lilly, which has had no editorial input into the content. Medthority received educational funding from the sponsor in order to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content.